Clinical trials: Age-Related Macular Degeneration
Neovascular Age-Related Macular Degeneration (nAMD), Treatment-naïve
Durability of Three Monthly Loading Doses With Faricimab in Treatment-naïve Neovascular Age-related Macular Degeneration
Neovascular Age-Related Macular Degeneration (nAMD) is a one of the leading causes of irreversible vision loss among the elderly in developed countries.
- Trial name
- NCT06890026
- Testing
- Faricimab Injection [Vabysmo]
- Where
- Denmark
- Volunteers
- 742 people
- Sponsor
- Copenhagen University Hospital, Rigshospitalet
Neovascular Age-related Macular Degeneration
Study of Safety and Efficacy of Brolucizumab 6 mg Drug Product Intended for Commercialization in Patients With nAMD
The purpose of this extension study was to assess the safety and efficacy of the new formulation of brolucizumab 6 mg ophthalmic solution when given to the same patients who received brolucizumab in the core trial CRTH258A2301…
- Trial name
- NCT03386474
- Testing
- Brolucizumab 6 mg, Aflibercept 2 mg
- Where
- 65 sites in United States, Puerto Rico
- Volunteers
- 151 people
- Sponsor
- Novartis Pharmaceuticals
Diabetic Macular Edema
Pilot Study for the Evaluation of Intravitreal Infliximab in the Treatment of Diabetic Macular Edema
The purpose of this study is to determine if intravitreal infliximab is a safe and effective treatment for macular edema secondary to diabetes.
- Trial name
- NCT00959725
- Testing
- Infliximab (intravitreal, 2.0mg/0.05ml)
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Icahn School of Medicine at Mount Sinai
Macular Degeneration, Age Related, Geographic Atrophy
COmparison of Clarus and Optos Ultrawide Field Imaging Systems for Geographic Atrophy
The goal of this clinical trial is to compare measurements of geographic atrophy (GA) area between several types of imaging, in order to assess accuracy.
- Trial name
- COCO-GA (NCT05961332)
- Testing
- Spectralis FAF imaging, Optos imaging, Zeiss Clarus 700 imaging
- Where
- United States
- Volunteers
- 62 people
- Sponsor
- University of Wisconsin, Madison
Macular Edema
Impact of the Navilas ® Micropulse Laser Treatment for Macular Edema Within the CHU Brugmann Hospital Macular Edema
The Navilas® micropulse laser can be used to treat patients with macular edema and good visual acuity, which therefore do not fall within the indications for conventional treatments by intravitreal injections.
- Trial name
- NCT04857099
- Testing
- Data extraction from medical files
- Where
- Belgium
- Volunteers
- 23 people
- Sponsor
- Brugmann University Hospital
Retinal Hemorrhage, Macular Degeneration
Subretinal Lucentis for Hemorrhagic Age-related Macular Degeneration (AMD)
Visual outcomes of the eye with large subretinal hemorrhages (bleeding under the retina) due to Age-Related Macular Degeneration (AMD) are poor.
- Trial name
- NCT00538538
- Testing
- vitrectomy with subretinal lucentis
- Where
- United States
- Volunteers
- healthy volunteers welcome
- Sponsor
- Corewell Health East
Neovascular Age-related Macular Degeneration, Diabetic Macular Edema
Post Intravitreal Injection Topical NSAID vs. Patching
A prospective randomized trial, to evaluate post-injection comfort measures comparing topical NSAID (nepafenac 0.3% suspension) and patching.
- Conditions
- Neovascular Age-related Macular Degeneration, Diabetic Macular Edema, Retinal Vein Occlusion
- Trial name
- NCT03918590
- Testing
- nepafenac 0.3% suspension (Ilevro; Alcon, Fort Worth, TX), Theratears tear drop, (Akron, Ann 111 Arbor, MI), patching
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- The New York Eye & Ear Infirmary
Branch Retinal Vein Occlusion, Central Retinal Vein Occlusion
Intravitreal Ranibizumab 0.5MG, or 1.0mg for RVO With Macular Edema Previously Receiving Bevacizumab
This study examines two doses of Ranibizumab (0.5mg and 1.0mg) for the treatment of macular edema secondary to retinal vein occlusion in patients that have previously failed treatment with other macular edema treatments including…
- Conditions
- Branch Retinal Vein Occlusion, Central Retinal Vein Occlusion, Macular Edema
- Trial name
- RAVEN (NCT01471691)
- Testing
- ranibizumab 0.5mg, ranibizumab 1.0mg
- Where
- 4 sites in United States
- Volunteers
- 14 people
- Sponsor
- Hanscom, Thomas, M.D.
Wet Age-related Macular Degeneration
A Study to Evaluate the Efficacy and Safety of Intravitreal KSI-301 Compared With Intravitreal Aflibercept in Participants With Neovascular (Wet) Age-related Macular Degeneration (wAMD)
This Phase 3 study will evaluate the efficacy and safety of KSI-301 compared to aflibercept, in participants with neovascular (wet) age-related macular degeneration (wAMD)
- Trial name
- DAYLIGHT (NCT04964089)
- Testing
- KSI-301, Aflibercept
- Where
- 66 sites in United States, Puerto Rico
- Volunteers
- 557 people
- Sponsor
- Kodiak Sciences Inc
Age-Related Macular Degeneration, Lens, Intraocular
Implantation of SML in Patients With Dry Age-related Macular Degeneration and Myopic Maculopathy
Age-related macular degeneration (AMD) is the leading cause of irreversible vision loss in developed countries among people over 50 years of age. Myopic maculopathy is also an important cause of irreversible vision loss.
- Conditions
- Age-Related Macular Degeneration, Lens, Intraocular, Myopic Maculopathy
- Trial name
- NCT03882606
- Testing
- Scharioth Macula Lens (SML, Medicontur)
- Where
- Spain
- Volunteers
- 3 people
- Sponsor
- Consorci Sanitari de Terrassa
Macular Degeneration, Age Related
Evaluating Metabolic Changes Induced by PhotoBioModulation Through Spectrally Resolved Autofluorescence in Dry Age-Related Macular Degeneration Patients
The best treatment to prevent the evolution of early and intermediate forms of dAMD to atrophic degeneration is PhotoBioModulation (PBM).
- Trial name
- PBM-dAMD (NCT06582511)
- Where
- Italy
- Volunteers
- 30 people
- Sponsor
- Francesco Bandello
Diabetic Retinopathy, Macular Edema
ILM Peeling in PDR Patients Undergoing PPV for VH
Subjects undergoing ILM peeling during vitrectomy will have better visual acuity and lower rates of DME to control subjects
- Trial name
- NCT03660371
- Testing
- PPV/MP, PPV without MP
- Where
- Mexico
- Volunteers
- 258 people
- Sponsor
- Rush Eye Associates
Macular Degeneration
Pilot Study to Evaluate the Safety and Efficacy of Treatment With ORA102 Combined With Avastin (Bevacizumab) Versus Avastin Alone, in Patients With Neovascular Age Related Macular Degeneration (AMD)
This is s randomized, multi-center, double blind, 3 arm, phase I/II pilot study to evaluate the safety and efficacy of treatment with ORA102 combined with Avastin (Bevacizumab) versus Avastin alone, in patients with neo-vascular…
- Trial name
- NCT00745511
- Testing
- ORA102 and Avastin, Avastin
- Where
- 5 sites in Israel
- Volunteers
- 96 people
- Sponsor
- Ora Bio Ltd.
Age-related Macular Degeneration
Head Mounted Eye Tracking Aide for Loss of Central Vision (HETALCEV)
A device has been developed that has eye trackers integrated within the Head Mounted Display (HMD) and can remap text and images around the scotoma in real time to prevent information loss from a central scotoma.
- Trial name
- HETALCEV (NCT02829606)
- Testing
- small scotoma using Head Mounted Display No re-mapping, Large scotoma using Head Mounted Display PLUS re-mapping
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- University of Minnesota
Central Serous Chorioretinopathy, Irvine-Gass Syndrome
Results of Suprachoroidal Steroids Injections in Two Chorioretinal Diseases
Suprachoroidal injection is a safe way for intraocular drug delivery. It was used to treat various retinal conditions.
- Conditions
- Central Serous Chorioretinopathy, Irvine-Gass Syndrome, Pars Planitis, Cystoid Macular Edema
- Trial name
- NCT05337332
- Testing
- Triamcinolone Acetonide
- Where
- Egypt
- Volunteers
- 50 people
- Sponsor
- Benha University
Complement Mediated Diseases
First-In-Human Clinical Study of the C3 Complement Inhibitor AMY- 101 in Healthy Male Volunteers
Safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of a Single Ascending Dose (SAD) and a Multiple Dose (MD) of the complement inhibitor AMY-101.
- Trial name
- NCT03316521
- Testing
- AMY-101
- Where
- United States
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Amyndas Pharmaceuticals S.A.
Geographic Atrophy
A Prospective, Multicenter, Open-Label, Observational Phase 4 Study to Evaluate Real-World Safety, Tolerability, and Treatment Patterns of Pegcetacoplan (Syfovre) in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration
A Prospective, Multicenter, Open-Label, Observational Phase 4 Study to Evaluate Real-World Safety, Tolerability, and Treatment Patterns of Pegcetacoplan (Syfovre) in Patients with Geographic Atrophy Secondary to Age-Related…
- Trial name
- NCT06161584
- Testing
- Pegcetacoplan
- Where
- 34 sites in United States
- Volunteers
- 300 people
- Sponsor
- Apellis Pharmaceuticals, Inc.
Age - Related Macular Degeneration (AMD)
Effect of Fu's Subcutaneous Needling for Age-related Macular Degeneration
This pilot randomized controlled trial aims to evaluate the efficacy and safety of FSN in improving symptoms in patients with dAMD.38 eligible participants will be recruited and randomly assign them in a 1:1 ratio to the FSN…
- Trial name
- NCT07121127
- Testing
- FSN+Vitamin supplement, Vitamin Supplements
- Volunteers
- 38 people
- Sponsor
- Zhiming Yan
Dry Age-related Macular Degeneration, Geographic Atrophy
A Multiple Dose Study of Repeat Intravitreal Injections of GEM103 in Dry Age-related Macular Degeneration
This study is designed to investigate the safety, PK/PD, biomarker and early clinical effects of repeat GEM103 IVT injections.
- Conditions
- Dry Age-related Macular Degeneration, Geographic Atrophy, Macular Degeneration, Retinal Disease
- Trial name
- NCT04643886
- Testing
- GEM103
- Where
- 29 sites in United States
- Volunteers
- 62 people
- Sponsor
- Gemini Therapeutics, Inc.
Macular Edema With Central Retinal Vein Occlusions
NEWTON: Aflibercept Injection for Previously Treated Macular Edema Associated With Central Retinal Vein Occlusions
The purpose of the study is to determine the effect of Intravitreal Aflibercept Injection (IAI) on previously treated Central Retinal Vein Occlusions (CRVOs) with other Anti-VEGF agents.
- Trial name
- NEWTON (NCT01870427)
- Testing
- Aflibercept (2.0 mg)
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Northern California Retina Vitreous Associates
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.